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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER1641Clinical and Genetic Issues in Familial Dilated CardiomyopathyRay E. Hershberger, Jill D. Siegfried
Hershberger and Siegfried review the recent progress in understanding the genetics of familial
dilated cardiomyopathy (FDC). A consensus has emerged that clinical screening of first-
degree family members will reveal FDC in at least 20% to 35% of cases of presumed
idiopathic dilated cardiomyopathy (IDC). Point mutations in 31 autosomal and 2 X-linked
genes representing diverse gene ontogeny have been implicated as causing FDC, but these
account for only 30% to 35% of cases. New mutations are being identified with faster and less
expensive gene-sequencing technologies. Guidelines for the evaluation and testing of FDC
and IDC are now available, and when combined with FDC genetic testing and counseling,
should greatly enhance our knowledge of cardiovascular genetic medicine.CLINICAL RESEARCH INTERVENTION IN VALVE DISEASE1650Sustained Clinical and Hemodynamic Benefits of TAVILutz Buellesfeld, Ulrich Gerckens, Gerhard Schuler, Raoul Bonan, Jan Kovac, Patrick W. Serruys,
Marino Labinaz, Peter den Heijer, Michael Mullen, Wayne Tymchak, Stephan Windecker, Ralf Mueller,
Eberhard Grube
Buellesfeld and colleagues evaluated the long-term safety and performance of the Medtronic
CoreValve prosthesis (Medtronic, Minneapolis, Minnesota) for transcatheter aortic valve
implantation (TAVI). A total of 126 patients underwent the TAVI procedure; retrospective
risk stratification classified 43% as moderate surgical risk, 41% as high-risk operable, and 16%
as high-risk inoperable. The 30-day all-cause mortality was 15%. The 2-year all-cause
mortality was 28% in the moderate-risk group and 46% in the high-risk group, with the
difference mainly due to noncardiac mortality. There was no incidence of structural valve
deterioration, and hemodynamic benefits remained stable. TAVI provides sustained clinical
and hemodynamic benefits in patients with symptomatic severe aortic stenosis at increased
risk for surgery.(continued on page A-27)
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tINTERVENTION IN VALVE DISEASE1658Acute Hemodynamic Effects of MitraClip Therapy for Mitral RegurgitationRobert J. Siegel, Simon Biner, Asim M. Rafique, Michael Rinaldi, Scott Lim, Peter Fail,
James Hermiller, Richard Smalling, Patrick L. Whitlow, Howard C. Herrmann, Elyse Foster,
Ted Feldman, Donald Glower, Saibal Kar, for the EVEREST Investigators
Siegel and colleagues studied the acute hemodynamic effects of mitral valve (MV) repair with
the MitraClip device (Evalve Inc., Menlo Park, California) in 100 subjects with severe mitral
regurgitation. Pre- and post-procedural hemodynamic parameters were studied invasively and
with echocardiography. Successful MitraClip treatment resulted in an increase in cardiac
output, an increase in forward stroke volume, and a decrease in systemic vascular resistance.
There was also acute left ventricular (LV) unloading with a decrease in LV end-diastolic
pressure and volume. Successful MV repair with the MitraClip system results in an
immediate hemodynamic improvement.RISK REDUCTION THERAPY
1666Reduced Cardiovascular Risk for Patients
Attaining LDL-C Levels Below 50 mg/dl With RosuvastatinJudith Hsia, Jean G. MacFadyen, John Monyak, Paul M. Ridker
The safety and magnitude of cardiovascular risk reduction conferred by treatment to low-
density lipoprotein cholesterol (LDL-C) levels below 70 mg/dl is uncertain. Hsia and
colleagues performed a post-hoc analysis of the JUPITER (Justification for the Use of Statins
in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial with subjects randomly
allocated to rosuvastatin 20-mg daily or placebo. For this analysis, subjects were stratified by
whether or not they had an LDL-C level 50 mg/dl. During a median follow-up of 2 years,
the hazard ratio for the primary endpoint compared with placebo was 0.76 for those assigned
to rosuvastatin who did not have an LDL-C level 50 mg/dl and 0.36 for those who did.
ates of myalgia, muscle weakness, neuropsychiatric conditions, cancer, and diabetes were not
ignificantly different in those with and without LDL-C 50 mg/dl. These results suggest
hat pursuing LDL-C 50 mg/dl may safely confer additional cardiovascular risk reduction.HEART FAILURE
1676Pharmacotherapy of HFpEF Improves
Exercise Tolerance But Not Mortality in Meta-AnalysisDavid J. Holland, Dharam J. Kumbhani, Salim H. Ahmed, Thomas H. Marwick
Treatment strategies for heart failure with preserved ejection fraction (HFpEF) remain
unproven despite several large-scale trials. Holland and colleagues performed a systematic
review to determine whether pharmacologic interventions changed exercise capacity, diastolic
function, and mortality in HFpEF. Data from 53,878 patients enrolled in 30 published
reports (18 randomized controlled trials [RCTs], 12 observational) were collated. In the
RCTs, exercise tolerance was improved by medical therapy, but E/A ratio was not. Over a
mean follow-up of 19 months, all-cause mortality was not improved by therapy. Pharmacotherapy
of HFpEF with a variety of different therapies may improve exercise tolerance, but none so
far improve mortality.Editorial Comment: Dalane W. Kitzman, p. 1687
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EEPIDEMIOLOGY1690Community Prevalence of Ideal Cardiovascular Health, by the AHA DefinitionAaron R. Folsom, Hiroshi Yatsuya, Jennifer A. Nettleton, Pamela L. Lutsey, Mary Cushman,
Wayne D. Rosamond, for the ARIC Study Investigators
An American Heart Association committee recently developed definitions of ideal,
intermediate, or poor cardiovascular health based on 7 cardiovascular disease (CVD) risk factors
r health behaviors. Folsom and colleagues used data from the ARIC (Atherosclerosis Risk in
ommunities) study, with data collected from the 1987 to 1989 cohort, to estimate the
revalence of ideal cardiovascular health and the subsequent rates of CVD during follow-up.
nly 0.1% of patients had ideal cardiovascular health, 17% had intermediate cardiovascular
ealth, and 82% had poor cardiovascular health. CVD incidence rates showed a graded
elation with the ideal, intermediate, and poor categories.ditorial Comment: Dariush Mozaffarian, p. 1697EXPEDITED PUBLICATION EXPEDITED PUBLICATION1700Novel Platinum Chromium EES Noninferior to Cobalt-Chromium DesignGregg W. Stone, Paul S. Teirstein, Ian T. Meredith, Bruno Farah, Christophe L. Dubois,
Robert L. Feldman, Joseph Dens, Nobuhisa Hagiwara, Dominic J. Allocco, Keith D. Dawkins,
for the PLATINUM Trial Investigators
A novel platinum chromium everolimus-eluting stent (EES) has been developed to improve
the mechanical and physical properties of the cobalt chromium EES, including vessel
conformability, side-branch access, radiopacity, radial strength, and fracture resistance. The
PLATINUM (A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-
Eluting Coronary Stent System [PROMUS Element] for the Treatment of up to two De
Novo Coronary Artery Lesions) trial compared the 2 versions of the stent in a noninferiority
trial of simple de novo lesions. The primary endpoint was the 12-month rate of target lesion
failure (TLF), a composite of target vessel-related cardiac death, target vessel-related
myocardial infarction, or ischemia-driven target lesion revascularization. The results showed
similar rates of TLF, with nonsignificant differences in measures of safety and efficacy
through 12 months.
